Gilead Slaps Rivals With Patent Suit Over HIV Drug

By Jasmin Jackson (May 10, 2022, 5:02 PM EDT) -- Gilead Sciences Inc. has initiated a drug patent suit against a trio of competitors in Delaware federal court, seeking to block three generic versions of its human immunodeficiency virus treatment Biktarvy.

Gilead said in a complaint Monday that its rivals — Lupin Ltd., Laurus Labs Ltd. and Cipla Ltd. — have each sought approval from the U.S. Food and Drug Administration to produce their own versions of the HIV-1 medication before Gilead's market exclusivity times out.

The pharmaceutical maker contends that its competitors' trio of abbreviated new drug applications, or ANDAs, infringe three drug patents for Biktarvy, two of which don't...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!